• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Pharma R&D pipeline value jumps 18% to $493 billion

Report: Pharma R&D pipeline value jumps 18% to $493 billion

June 17, 2015
CenterWatch Staff

Emerging therapeutic categories and a string of breakthrough drug approvals are powering key drug sales across the U.S. and Europe, fueling a projected 5% increase in global prescription sales over the next five years, according to the EvaluatePharma World Preview 2015, Outlook to 2020 report from life science market intelligence firm Evaluate. With the FDA approving an unprecedented 50 drugs in 2014, eight of which are forecast to have sales of more than $1 billion five years after launch, sustained R&D productivity may finally be within reach.

“Any fears that the pharmaceutical industry might be heading toward a slowdown after the last two years of phenomenal growth can be put to rest for now,” said Lisa Urquhart, editor of EP Vantage, the editorial arm of Evaluate. “However, for the industry to sustain this impressive growth they will have to make compromises around global pricing and market access. As such, pharmaceutical companies need to either accept lower prices for its products, or persuade payers that the therapeutic benefits outweigh the cost of disease.”

Key report highlights include:

  • Worldwide prescription drug sales to reach nearly one trillion dollars by 2020 with a CAGR of 4.8% between 2014 and 2020
  • 2014 U.S. prescription drug sales surge 8.9%; Europe returns to growth with a 2.4% jump, while Japanese sales in yen dropped by 2.6%
  • R&D pipeline values increase to $492.8 billion from $418.5 billion in 2014; Gilead’s potential new combination hepatitis C product valued highest at $24.8 billion
  • Humira remained the top-selling product in 2014 with sales of $13.9 billion; Sovaldi debuts at number two with sales of $10 billion
  • FDA approves record-breaking 50 new drugs in 2014 with a 43% increase in five-year post-launch sales potential; Bristol-Myers Squibb’s Opdivo was the number one approval
  • Novartis will remain the number one pharmaceutical company through 2020 with total prescription drug sales of $53.3 billion
  • Value of M&A transactions almost doubled to $116 billion in 2014; value of venture financing deals leapt 36% to $8.2 billion.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing